& Neale, P
Tirzepatide's dual action typically produces numerically higher weight loss percentagesaveraging 16-22% versus semaglutide's 10-15%though individual variation remains substantial and direct comparison requires provider assessment
In one Phase 2 trial of people with obesity, called VISTA, those on the highest dose of the drug, called elecoglipron, lost 11.2% of their weight after 36 weeks, when looking at all patients regardless of discontinuations, according to data presented Monday at the annual meeting of the American Diabetes Association and published in the Lancet
This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce healthcare costs to our nation, the White House wrote in a statement
So when we look at this, when we look at it through the lens, what you were asking me about with long Covid, with MCAS, etc